News

• Phase 1b/2a trial of NervGen’s lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury
• “The ability of NVG-291 to demonstrate meaningful recovery in motor function, sensory function and bladder control in animal models is exceptional. If these results translate to patients, NVG-291 could redefine the treatment of spinal cord injury.” – Dr. Monica Perez, Shirley Ryan AbilityLab
• NervGen plans to include acute/subacute and chronic spinal cord injury patients in its clinical trial

Vancouver, Canada January 10, 2022 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce it has entered into a Memorandum of Understanding with Shirley Ryan AbilityLab with the intention of performing NervGen’s first clinical trial with the Company’s proprietary NVG-291 in spinal cord injury (SCI) patients. The single site clinical trial, which is expected to start in the second half of 2022, will be a placebo-controlled trial, assessing the safety and efficacy of NVG-291 in treating acute/subacute (<3 months post-injury) and chronic (≥1 year post-injury) patients. In two independent animal studies published in Nature and Experimental Neurology, NVG-291 treatment resulted in significant recovery in mobility and/or bladder function, despite experiencing a debilitating spinal cord injury.

Cincinnati, Ohio January 4, 2022 – NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds President Biden for signing the Fiscal Year 2022 National Defense Authorization Act (FY22 NDAA) into law on December 27^th, 2021. The Senate report accompanying the legislation included specific encouragement to the Department of Defense (DoD) to fund traumatic brain injury (TBI) research related to neuroplasticity therapeutics. The President’s signature now allows the DoD to move forward with that research.

• Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen’s NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer’s disease indications
• Screening of healthy volunteers has already started for the trial’s multiple ascending dose (MAD) portion
• In preclinical studies, NVG-291 has been shown to promote repair of nervous system damage

Vancouver, Canada. December 22, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments that repair nervous system damage, is pleased to announce it has received ethics board approval from Bellberry Limited’s Human Research Ethics Committee (HREC) to proceed with the multiple ascending dose (MAD) portion of its Phase 1 trial with its lead compound, NVG-291.

Vancouver, Canada. November 29, 2021— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”) of 892,721 units of the Company at a price of CA$2.60 per unit, for aggregate gross proceeds to the Company of CA$2,321,075.

Vancouver, Canada. November 18, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended September 30, 2021.

Vancouver, Canada November 12, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public offering (the “Offering”) including the full exercise of the underwriters’ over-allotment option. The Offering was made pursuant to an underwriting agreement entered into with a syndicate of underwriters led by iA Private Wealth Inc. and including Canaccord Genuity Corp. and Paradigm Capital Inc. (collectively, the “Underwriters”).

Vancouver, Canada November 5, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that, due to strong demand, the Company has agreed with a syndicate of underwriters led by iA Private Wealth Inc. and including Canaccord Genuity Corp. and Paradigm Capital Inc. (collectively, the “Underwriters”), to increase the size of its previously announced $5,000,000 bought deal offering. Pursuant to the upsized deal terms, the Underwriters have agreed to purchase, on a “bought deal” basis, 3,200,000 units (the “Units”) at a price of C$2.50 per Unit (the “Issue Price”) for aggregate gross proceeds to the Company of $8,000,000 (the “Offering”). Each Unit will be comprised of one common share of the Company (the “Common Shares”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share in the capital of the Company (a “Warrant Share”) for a period of 24 months following the closing of the Offering at an exercise price of C$3.20 per Warrant Share.

Vancouver, Canada November 4, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that it has entered into an agreement with iA Private Wealth Inc. as lead underwriter  and  bookrunner,  on  behalf of a syndicate of underwriters including Canaccord Genuity Corp. and Paradigm Capital Inc. (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” basis, 2,000,000 units (the “Units”) at a price of C$2.50 per Unit (the “Issue Price”), each Unit being comprised of one common share of the Company (the “Common Shares”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”) for aggregate gross proceeds to the Company of approximately $5,000,000 (the “Offering”). Each Warrant will be exercisable to acquire one common share in the capital of the Company (a “Warrant Share”) for a period of 24 months following the closing of the Offering at an exercise price of C$3.20 per Warrant Share.

Vancouver, Canada. November 4, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience’s Neuroscience 2021 conference. NervGen’s Chief Medical Officer, Dr. Daniel Mikol, presented blinded safety and pharmacokinetic data, including new data for the highest single ascending dose (SAD) cohort that demonstrated that NVG-291 was well tolerated and had favorable pharmacokinetic properties. NervGen is also pleased to announce that, after completing the six planned SAD cohorts, the safety review committee overseeing the study has recommended that the Company proceed to the multiple ascending dose (MAD) portion of the trial.

Vancouver, Canada. October 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board comprised of five world-class scientific and clinical researchers in the field of spinal cord injury: Drs. James Guest, Steven Kirshblum, Brian Kwon, Linda Jones and Daniel Lammertse. This Clinical Advisory Board will work closely with NervGen as the Company prepares for its upcoming Phase 1b/2 clinical trial for spinal cord injury with its lead compound, NVG-291.

Vancouver, Canada. October 18, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided a positive update on its Phase 1 program with NVG-291 in healthy volunteers at the 146th Annual Meeting of the American Neurological Association. NervGen’s Chief Medical Officer, Dr. Daniel Mikol, presented interim blinded data from the single ascending dose (SAD) cohort of the study that demonstrated that NVG-291 was well tolerated and had favorable pharmacokinetic properties.

Cincinnati, Ohio. October 4, 2021 – NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the United States Senate Armed Services Committee for its release of the Fiscal Year 2022 National Defense Authorization Act (FY 22 NDAA) and the accompanying report language related to traumatic brain injury (TBI).

Vancouver, Canada. September 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a partnership with Imeka Solutions Inc. (“Imeka”), currently the only neuroimaging company that combines artificial intelligence and diffusion imaging to obtain high resolution images of white matter in the brain. NervGen intends to utilize Imeka’s imaging technology as a sensitive pharmacodynamic biomarker for its lead compound, NVG-291, in its Phase 1b/2 clinical trials. Additionally, the companies are submitting non-dilutive grants that support combining their technologies in preclinical and clinical studies for various conditions related to central nervous system damage.

Vancouver, Canada. September 14, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 550,000 incentive stock options to Directors exercisable at a price of $2.10 per share for a period of five years with vesting that is either time or performance based. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company’s stock option plan.

Vancouver, Canada. September 12, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.

Vancouver, Canada. September 10, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the results of its Annual General Meeting of Shareholders (“AGM”) held on September 9, 2021.

Vancouver, Canada. August 19, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial results for the second quarter ended June 30, 2021.

Vancouver, Canada. August 9, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease.

Vancouver, Canada. August 5, 2021— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”) of 1,511,636 units of the Company at a price of CAD$1.55 per unit, for aggregate gross proceeds to the Company of CAD$2,343,036.

Vancouver, Canada. July 16, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisable at $2.00 per share for a period of three years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company’s stock option plan.

Vancouver, Canada. July 15, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the formation of its Multiple Sclerosis (MS) Clinical Advisory Board comprised of six world-class scientific and clinical researchers in the field of multiple sclerosis: Drs. Jack Antel, Peter Calabresi, Jeremy Chataway, Jeffrey Cohen, Robert Naismith and Anneke van der Walt. This Clinical Advisory Board will work closely with NervGen as the Company prepares for its upcoming Phase 2 clinical trial in MS with its lead compound, NVG-291.

Vancouver, Canada. July 12, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researchers to its Alzheimer’s Disease Scientific Advisory Board.  Drs. Martin Farlow, Reisa Sperling and Michael Weiner have agreed to join Drs. Jeffrey Cummings, Bruce Lamb, George Perry and Henrik Zetterberg on the Alzheimer’s Disease Scientific Advisory Board to guide NervGen as it prepares for the Phase 1b clinical trial of its lead compound, NVG-291, in Alzheimer’s patients that is slated to begin in 2022.

Vancouver, Canada. June 25, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced that it has engaged Vorticom Inc. (“Vorticom”), a New York based full-service public relations agency to provide media relations and related services for the Company.

Vancouver, Canada. June 10, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research agreement with Sylics Contract Research (“Sylics”), a contract research organization specializing in testing novel therapies in the field of neurosciences, to study the effects of NVG-291 in mouse models of Alzheimer’s disease.

Vancouver, Canada. May 20, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021.

Vancouver, Canada. May 12, 2021 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, announced that it has closed its previously announced overnight, “best efforts” marketed public offering (the “Offering”) of units (the “Units”). Pursuant to the Offering, NervGen issued an aggregate of 3,250,000 units of the Company at a price of C$1.55 per Unit for aggregate gross proceeds of C$5,037,500. Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant is exercisable at a price of C$2.10 and entitles the holder thereof to acquire one common share of the Company for a period of 2 years following the closing of the Offering.

Vancouver, Canada. May 7, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, today announced that the Company has granted 800,000 incentive stock options to an Officer of the Company exercisable at a price of $1.51 per share for a period of 10 years and that vest equally every six months over a two-year period.

Vancouver, Canada. May 6, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 in the Company’s Phase 1 clinical trial in healthy volunteers.

Vancouver, Canada. May 5, 2021 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has priced its previously announced overnight, “best efforts” marketed public offering (the “Offering”) of units (the “Units”).  Pursuant to the Offering, NervGen will issue an aggregate of up to 3.25 million units of the Company at a price of C$1.55 per Unit for aggregate gross proceeds of up to approximately C$5 million. Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant is exercisable at a price of C$2.10 and entitles the holder thereof to acquire one common share of the Company (a “Warrant Share”) for a period of 2 years following the closing of the Offering.

Vancouver, Canada. May 4, 2021 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has launched an overnight, “best efforts” marketed public offering (the “Offering”) of units (the “Units”), each Unit being comprised of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). The number of Units to be distributed under the Offering, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market.

Vancouver, Canada. April 23, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 306,000 incentive stock options to Employees and Officers exercisable at a price of $1.65 per share for a period of 10 years and that vest equally every six months over a two-year period.

Vancouver, Canada. April 22, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce the appointment of Daniel Mikol, MD, PhD, as the Company’s Chief Medical Officer, effective May 5^th, 2021. Dr. Mikol, who currently holds the position of Executive Medical Director, Global Clinical Development at Amgen, will oversee NervGen’s medical and clinical activities, with a primary focus on NervGen’s lead product, NVG-291, which is initially being developed to treat multiple sclerosis, Alzheimer’s disease and spinal cord injury.

Vancouver, Canada. April 14, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and guidance from the Bellberry Human Research Ethics Committee (“HREC”) in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific and selective protein tyrosine phosphatase sigma (“PTPσ”) inhibitor.

Vancouver, Canada. April 8, 2021– NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.